Virginia Palomar Coloma

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 609 citations

Medicine, Oncology, Pharmacotherapy +16

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Sandrine Aspeslagh, Margarida Matias, Virginia Palomar Coloma et al. · European Journal of Cancer · 2017 · 23 citations

Life Sciences, Immunology, Oncology +16

Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors.

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Journal of Clinical Oncology · 2016 · 12 citations

Medicine, Oncology, Pharmacology +17

High incidence of cetuximab-related infusion reactions in head and neck patients

Virginia Palomar Coloma, Pamela Eguiguren Bravo, Naima Lezghed et al. · ESMO Open · 2018 · 12 citations · Full text

Pharmacy, Oncology, Pharmacology +15